Catalyst

Slingshot members are tracking this event:

Stryker receives FDA 510(k) clearance for its Tritanium PL Posterior Lumbar Cage for use in spinal fixation in patients with degenerative disc disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SYK Community voting in process

Additional Information

Additional Relevant Details The Tritanium PL posterior lumbar cages are constructed out of proprietary Tritanium technology used by Stryker’s Spine division and are manufactured via a 3D additive manufacturing process. Tritanium is a novel highly porous titanium material designed for bone in-growth and biologic fixation in spine applications.Tritanium PL Cages are offered in a variety of widths, lengths, heights, and lordotic angles designed to adapt to a variety of patient anatomies and are designed to be implanted via a posterior approach. The cage is intended for use in patients with degenerative disc disease, grade I spondylolisthesis, and degenerative scoliosis. Degenerative disc disease is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies.The large lateral windows and open architecture of the Tritanium PL Cage allow visualization of fusion on CT and X-ray. Its solid-tipped, precisely angled serrations are designed for bidirectional fixation and to maximize surface area for endplate contact with the implant. The Tritanium PL Cage is also designed to address the potential for subsidence into the endplates.
http://www.businessw...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tritanium Pl Posterior Lumbar Cage, Spinal Fixation, Degenerative Disc Disease, Porous Titanium Material